Targeted Treatment of Differentiated and Medullary Thyroid Cancer
نویسندگان
چکیده
منابع مشابه
Targeted Treatment of Differentiated and Medullary Thyroid Cancer
The incidence of thyroid cancer is increasing, with a concomitant increase in the number of patients with advanced and metastatic disease. Discoveries regarding the pathogenesis of thyroid cancer have led to the recent development of new therapeutic agents that are beginning to appear on the market. Many of these new agents are targeted kinase inhibitors primarily affecting oncogenic kinases (B...
متن کاملGenetic and Epigenetic of Medullary Thyroid Cancer
Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we shed light on all the genetic and epigenetic hallmarks of MTC. From the genetic perspective, RET, ...
متن کاملMedullary Thyroid Cancer: A Review
Thyroid cancer is a malignancy of the thyroid parenchymal cells. There are four main types of thyroid cancer: papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid carcinoma (ATC), and Medullary thyroid carcinoma (MTC). Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor of the thyroid gland derived from parafollicular C-cells that produce calcitonin (CT...
متن کاملTreatment of advanced medullary thyroid cancer
Therapy decisions in advanced medullary thyroid carcinoma should be guided by a critical appraisal of the natural disease course (slowly progressive vs. aggressive) and benefits and side effects of therapy. Therapy goals should be distinguished between curative and palliative. Local treatments are mainly palliative and may add to quality of life. The advent of novel systemic therapies opens pro...
متن کاملI-124 pre-therapy dosimetry for the treatment of differentiated thyroid cancer: A single center experience
Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thyroid Research
سال: 2011
ISSN: 2042-0072
DOI: 10.4061/2011/102636